Twist Bioscience (NASDAQ:TWST) SVP Sells $217,564.80 in Stock

Twist Bioscience Corporation (NASDAQ:TWST) SVP Paula Green sold 6,920 shares of Twist Bioscience stock in a transaction that occurred on Thursday, October 30th. The stock was sold at an average price of $31.44, for a total value of $217,564.80. Following the transaction, the senior vice president owned 143,271 shares of the company’s stock, valued at $4,504,440.24. This represents a 4.61% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Paula Green also recently made the following trade(s):

• On Monday, November 3rd, Paula Green sold 1,084 shares of Twist Bioscience stock. The shares were sold at an average price of $32.08, for a total value of $34,774.72.
• On Monday, October 6th, Paula Green sold 9,724 shares of Twist Bioscience stock. The stock was sold at an average price of $32.19, for a total transaction of $313,015.56.
• On Monday, September 22nd, Paula Green sold 295 shares of Twist Bioscience stock. The shares were sold at an average price of $27.56, for a total transaction of $8,130.20.
• On Monday, September 8th, Paula Green sold 892 shares of Twist Bioscience stock. The stock was sold at an average price of $25.76, for a total value of $22,977.92.

Twist Bioscience Price Performance

Twist Bioscience stock opened at $31.52 on Thursday. The company has a market capitalization of $1.90 billion, a price-to-earnings ratio of -21.74 and a beta of 2.43. The company has a current ratio of 3.90, a quick ratio of 3.60 and a debt-to-equity ratio of 0.03. Twist Bioscience Corporation has a 12 month low of $24.07 and a 12 month high of $55.33. The stock’s 50 day moving average is $29.18 and its 200-day moving average is $31.74.

Twist Bioscience (NASDAQ:TWST) last posted its quarterly earnings data on Monday, August 4th. The company reported ($0.47) earnings per share for the quarter, topping the consensus estimate of ($0.54) by $0.07. The firm had revenue of $96.06 million for the quarter, compared to analysts’ expectations of $95.52 million. Twist Bioscience had a negative return on equity of 29.03% and a negative net margin of 23.51%. Equities research analysts expect that Twist Bioscience Corporation will post -2.12 EPS for the current year.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the company. Mirae Asset Global Investments Co. Ltd. grew its position in Twist Bioscience by 15.0% during the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,315 shares of the company’s stock worth $85,000 after acquiring an additional 302 shares during the last quarter. GAMMA Investing LLC grew its holdings in shares of Twist Bioscience by 68.1% during the first quarter. GAMMA Investing LLC now owns 748 shares of the company’s stock worth $29,000 after purchasing an additional 303 shares during the last quarter. D.A. Davidson & CO. increased its stake in shares of Twist Bioscience by 1.5% in the second quarter. D.A. Davidson & CO. now owns 23,062 shares of the company’s stock valued at $848,000 after buying an additional 352 shares during the period. Smartleaf Asset Management LLC raised its holdings in Twist Bioscience by 70.6% in the 3rd quarter. Smartleaf Asset Management LLC now owns 1,068 shares of the company’s stock valued at $29,000 after buying an additional 442 shares during the last quarter. Finally, California State Teachers Retirement System boosted its position in Twist Bioscience by 0.8% during the 2nd quarter. California State Teachers Retirement System now owns 54,187 shares of the company’s stock worth $1,994,000 after buying an additional 442 shares during the period.

Analyst Upgrades and Downgrades

TWST has been the subject of several analyst reports. Cowen reaffirmed a “buy” rating on shares of Twist Bioscience in a report on Monday, August 4th. Stephens began coverage on shares of Twist Bioscience in a research report on Monday. They set an “overweight” rating and a $41.00 price objective for the company. Evercore ISI reduced their price target on shares of Twist Bioscience from $46.00 to $42.00 and set an “outperform” rating on the stock in a research report on Tuesday, October 7th. Barclays lowered their price objective on shares of Twist Bioscience from $45.00 to $40.00 and set an “overweight” rating for the company in a research report on Thursday, October 2nd. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Twist Bioscience in a research note on Wednesday, October 8th. Ten investment analysts have rated the stock with a Buy rating and two have given a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $47.80.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.